There may not be hardly any, but it could be they can do it as censored data, if regulators agreed, imho, but I don’t know. I mean, if they are not GBM, they’re not GBM.
I think it’s a good sign LL already was thinking years ago that idh mutant tumors should not be classified as GBM tumors. Maybe there aren’t any in our trial (or very few).
It would also make the longevity in the phase iii trial that much more impressive, because typically longer lived patients with idh mutant tumors wouldn’t have padded our results.
News 
Market Data 
Discover 
